Lymphoma is a group of hematological malignancies that contributes significantly to global morbidity and mortality. A key therapeutic target in lymphoma is the B-cell lymphoma 2 (Bcl-2) protein, which functions as an anti-apoptotic agent, thereby promoting cancer cell survival. This study aimed to evaluate five natural compounds (curcumin, resveratrol, genistein, luteolin, and quercetin) as potential Bcl-2 inhibitors using an in-silico approach. The compounds were assessed through drug-likeness screening (SwissADME), toxicity prediction (ProTox-II), and molecular docking and interaction analysis (Biovia Discovery Studio). Venetoclax served as the positive control. All compounds complied with Lipinski's Rule of Five (allowing for a maximum of one violation) and demonstrated safe toxicity profiles. Docking results against the target protein (PDB ID: 6GL8) revealed that quercetin and luteolin exhibited excellent binding affinities, comparable to that of the positive control. The interactions were predominantly characterized by hydrogen bonding and hydrophobic interactions within the active site of the target protein. These findings provide a foundation for the development of novel therapeutic agents for lymphoma.
Copyrights © 2026